XJPX
4202
Market cap2.20bUSD
Jul 09, Last price
1,400.50JPY
1D
-0.43%
1Q
10.10%
Jan 2017
8.57%
Name
Daicel Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Daicel Corporation, a globally active company founded in Osaka, Japan, in 1919, operates across diverse sectors including medical/healthcare, smart technologies, safety solutions, advanced materials, and engineering plastics. Its extensive product range serves various industries across Japan, China, and international markets. The company provides cosmetic ingredients like 1,3-Butylene glycol and polyglycerin, alongside specialized chiral and achiral columns, analytical tools, reagents, and comprehensive services for analysis, purification, and synthesis. For the electronics industry, Daicel offers high-performance films, solvents for electronic materials, resist polymers, semiconductor cleaning agents, optical components, silver nanoparticle inks, and organic semiconductor devices. In safety applications, their portfolio includes inflators, pyro-fuses, and safety devices designed for non-mobility products. They also manufacture a wide array of chemical products such as acetic acid and its derivatives, cellulose acetate, cycloaliphatic epoxies, and caprolactone. Additionally, Daicel contributes to the health and wellness sector with nutraceuticals like ceramide from konjac root, equol from soybeans, and specialized supplement formulations such as DiSPERZiSTA. Their offerings further encompass engineering plastics, high-performance polymers, functional sheets, and packaging films, alongside advanced water treatment systems like UF membrane modules and ultra-fine bubble diffusers. These innovative products are vital for applications in transportation, electronics, medical care, personal care, daily life, and environmental and energy management. Formerly known as Daicel Chemical Industries, Ltd., the company adopted its current name in October 2011.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||